Skip to main content
. 2018 May 29;9:1051. doi: 10.3389/fimmu.2018.01051

Figure 6.

Figure 6

Indoleamine 2,3-dioxygenase (IDO) tumor-specific expression is a strong prognostic factor for biochemical recurrence (BR) in prostate cancer (PCa). (A) Receiver operating characteristic (ROC) curve analysis was used to evaluate the prognostic relevance of IDO gene expression. The area under the curve for recurrence-free survival (RFS) was 0.78 (95% CI, 0.67–0.88%) with an optimal cutoff level of 9.83 × 10−4 to dichotomize the patients into IDOhigh and IDOlow groups (specificity 78%, sensitivity 67%). (B) Kaplan–Meier estimates of RFS stratified by the established cutoff for IDO gene expression in PCa tissue specimens (IDO 9.83 × 10−4). The survival analysis was based on time of BR (RFS with a median survival of 29 months; 95% CI, 22–36%; p < 0.0001, two-sided log rank test). (C) IDO gene expression in PCa tissue specimens was higher in BR-positive than in BR-negative patients (p < 0.001, Mann–Whitney U test), with a clear association between IDO gene levels and evidence of BR (prostate-specific antigen ≥ 0.1 ng/ml) (Pearson χ2 test).